Myrthala Moreno-Smith
Overview
Explore the profile of Myrthala Moreno-Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Goethem A, Deleu J, Yigit N, Everaert C, Moreno-Smith M, Vasudevan S, et al.
NAR Cancer
. 2023 Jan;
5(1):zcad002.
PMID: 36683916
Accurate assessment of treatment response and residual disease is indispensable for the evaluation of cancer treatment efficacy. However, performing tissue biopsies for longitudinal follow-up poses a major challenge in the...
2.
Tao L, Mohammad M, Milazzo G, Moreno-Smith M, Patel T, Zorman B, et al.
Nat Commun
. 2022 Jun;
13(1):3728.
PMID: 35764645
Neuroblastoma (NB) is a childhood cancer arising from sympatho-adrenal neural crest cells. MYCN amplification is found in half of high-risk NB patients; however, no available therapies directly target MYCN. Using...
3.
Tao L, Moreno-Smith M, Ibarra-Garcia-Padilla R, Milazzo G, Drolet N, Hernandez B, et al.
Adv Sci (Weinh)
. 2021 Aug;
8(19):e2005047.
PMID: 34365742
Neuroblastoma (NB) arises from oncogenic disruption of neural crest (NC) differentiation. Treatment with retinoic acid (RA) to induce differentiation has improved survival in some NB patients, but not all patients...
4.
Moreno-Smith M, Lu C, Shahzad M, Pena G, Allen J, Stone R, et al.
Clin Cancer Res
. 2021 Aug;
27(15):4451.
PMID: 34341056
No abstract available.
5.
Foster J, Barbieri E, Zhang L, Scorsone K, Moreno-Smith M, Zage P, et al.
Int J Mol Sci
. 2021 Jul;
22(12).
PMID: 34207315
Pevonedistat is a neddylation inhibitor that blocks proteasomal degradation of cullin-RING ligase (CRL) proteins involved in the degradation of short-lived regulatory proteins, including those involved with cell-cycle regulation. We determined...
6.
Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad M, et al.
Nat Commun
. 2021 Jun;
12(1):4006.
PMID: 34183658
MYCN activation is a hallmark of advanced neuroblastoma (NB) and a known master regulator of metabolic reprogramming, favoring NB adaptation to its microenvironment. We found that the expression of the...
7.
Yi J, Sias-Garcia O, Nasholm N, Hu X, Iniguez A, Hall M, et al.
Neoplasia
. 2021 Jun;
23(6):624-633.
PMID: 34107377
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription....
8.
Moreno-Smith M, Halder J, Meltzer P, Gonda T, Mangala L, Rupaimoole R, et al.
J Clin Invest
. 2021 Apr;
131(7).
PMID: 33792569
No abstract available.
9.
Shahzad M, Arevalo J, Armaiz-Pena G, Lu C, Stone R, Moreno-Smith M, et al.
J Biol Chem
. 2018 Jul;
293(26):10041.
PMID: 29959278
No abstract available.
10.
Moreno-Smith M, Halder J, Meltzer P, Gonda T, Mangala L, Rupaimoole R, et al.
J Clin Invest
. 2018 May;
128(7):3199.
PMID: 29809169
No abstract available.